• Adolor Corp., of Exton, Pa., filed a shelf registration statement with the SEC. The registration would permit the company to offer and sell up to 7.5 million shares of common stock from time to time. Adolor specializes in the discovery, license, acquisition, development and commercialization of prescription pain management products. Adolor's stock (NASDAQ:ADLR) gained 4 cents Friday to close at $13.19.

• Bio-Rad Laboratories Inc., of Hercules, Calif., reported the results of its cash tender offer and consent solicitation for all of its outstanding 11 5/8 percent senior subordinated notes due 2007, which expired Friday at 12:01 a.m. The company received tenders from holders of about 97 percent of the notes subject to the tender offer and has accepted the notes for purchase. Bio-Rad distributes life science research products and clinical diagnostics.

• Corixa Corp., of Seattle, and Apovia AG, of Martinsried, Germany, formed a research, development and commercialization agreement for Corixa's synthetic adjuvant, RC-529. The multiyear agreement grants Apovia commercial rights to RC-529 for use in an undisclosed therapeutic vaccine. Both companies will equally share research, development and commercialization costs, as well as any potential product revenue. Financial terms were not disclosed. RC-529 is the lead adjuvant compound from Corixa's AGP chemical library.

• Elan Corp. plc, of Dublin, Ireland, has sought and received agreements from a majority of the holders of the guaranteed notes issued by Elan's qualifying special purpose entities, Elan Pharmaceutical Investments II Ltd. and Elan Pharmaceutical Investments III Ltd. The agreements extend to Aug. 22 the EPIL II and EPIL III noteholders' waivers of compliance by Elan with certain provisions of the documents governing the EPIL II and EPIL III notes that required Elan to provide the noteholders with Elan's 2002 audited consolidated financial statements by June 29, 2003. The waivers were set to expire Friday. Elan paid an aggregate fee of about $2.1 million to the noteholders in connection with the waivers. Elan is working to conclude all audit-related issues and matters in order to complete its 2002 statement as soon as possible, it said.

• Ligand Pharmaceuticals Inc., of San Diego, said it has exceeded a 600-patient enrollment goal in the first of two pivotal Phase III studies of Targretin (bexarotene) capsules in front-line combination therapy to treat advanced non-small-cell lung cancer (NSCLC). The SPIRIT I (studies providing investigational research in Targretin) trial is being conducted at 94 sites worldwide and is designed to evaluate whether adding Targretin to front-line cisplatin/vinorelbine chemotherapy extends the lives of patients with advanced (Stage IIIB with pleural effusion or Stage IV) NSCLC. Ligand expects survival data from the study to be available in about one year. Targretin is approved to treat cutaneous T-cell lymphoma. Ligand's second Phase III Targretin study in advanced NSCLC (SPIRIT II) is examining the drug in front-line combination therapy with a different chemotherapy regimen, carboplatin and paclitaxel. It is about 88 percent enrolled.

• Neose Technologies Inc., of Horsham, Pa., entered an agreement with Sandoz in which Neose will use its technologies with a therapeutic recombinant protein that is manufactured and supplied by Sandoz, a unit of Novartis AG, of Basel, Switzerland. If both parties elect to proceed with further development and commercialization, they would have co-exclusive worldwide rights.

• Novavax Inc., of Columbia, Md., filed to sell up to $50 million in stock from time to time. It said in its prospectus that unless otherwise described, it expects to use proceeds for general corporate purposes. Novavax is focused on the research, development and commercialization of products using its drug delivery and vaccine technologies, concentrating on the areas of women's health and infectious diseases.

• Serologicals Corp., of Atlanta, priced its offering of $110 million aggregate principal amount of its 4.75 percent convertible senior subordinated debentures due 2033 in a private placement. Also, initial purchasers have an option to purchase up to another $20 million aggregate principal amount. The offering is expected to close Wednesday. The debentures are convertible into shares of Serologicals stock at a rate of about 67.6 shares per $1,000 principal amount of debentures, subject to adjustment. The debentures will mature on Aug. 15, 2033. Interest on the debentures will be payable at 4.75 percent annually on Feb. 15 and Aug. 15 each year, beginning next year. The company intends to use proceeds to repay all outstanding indebtedness under its existing credit facility and also for general corporate purposes.

• Vical Inc., of San Diego, filed a shelf registration statement with the SEC that would allow it to issue, from time to time, an aggregate of up to $50 million of common stock, preferred stock or a combination of both. The registration is intended to provide flexibility in financing the company's business needs, it said. Specific terms of any offering under the shelf registration and the securities involved would be established at the time of sale.